WINT - Windtree Therapeutics Inc logo

Windtree Therapeutics Inc

WINT

Windtree Therapeutics develops therapies for acute cardiovascular and pulmonary diseases. Key products include istaroxime for heart failure, AEROSURF for infant respiratory distress, and several preclinical candidates targeting various health conditions.

βš•οΈ Healthcare NASDAQ Listed 1995 $ USD
$1,000 invested 30 years ago β†’$0today

Score Overview

1 Year
Scoreβ€”
Net Growth-5x
Net TrendShrank
Net Income Consistencyβ€”
Rev Growthβ€”
Rev TrendGrew
Revenue Consistencyβ€”
5 Years
Scoreβ€”
Net Growth-32.11%
Net Trend60%
Net Income Consistencyβ€”
Rev Growthβ€”
Rev Trend20%
Revenue Consistencyβ€”
10 Years
Score
Net Growth27.49%
Net Trend50%
Net Income Consistency
Rev Growth-90.88%
Rev Trend30%
Revenue Consistency
20 Years
Score2.6
Net Growth32.09%
Net Trend55%
Net Income Consistency
Rev Growth-32.84%
Rev Trend36%
Revenue Consistency
30 Years
Score
Net Growth-12x
Net Trend43%
Net Income Consistency
Rev Growth-10.00%
Rev Trend50%
Revenue Consistency
All Time
Score
Net Growth-12x
Net Trend43%
Net Income Consistency
Rev Growth-10.00%
Rev Trend50%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Windtree Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Showing 20 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • WINT

2016: 98.2% Β· 2021: 99.5% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 0.00β€”
1 Year2025-09-29
$ 0.07-99.57%
5 Years2021-09-29
$ 90K-100.00%
10 Years2016-09-29
$ 1000K-100.00%
20 Years2006-09-29
$ 1000K-100.00%
30 Years1996-09-27
$ 1000K-100.00%
All Time1995-08-08
$ 1000K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 90K-$ 40M$ 204K
2024$ 0.00-$ 5M$ 1M
2023$ 0.00-$ 20M$ 4M
2022$ 0.00-$ 39M$ 6M
2021$ 0.00-$ 67M$ 22M
2020$ 0.00-$ 30M$ 16M
2019$ 198K-$ 27M$ 22M
2018$ 1M-$ 20M$ 25M
2017$ 1M-$ 18M$ 1M
2016$ 2M-$ 39M$ 5M
2015$ 987K-$ 55M$ 38M
2014$ 2M-$ 44M$ 44M
2013$ 388K-$ 45M$ 86M
2012$ 195K-$ 37M$ 26M
2011$ 582K-$ 20M$ 10M
2010-$ 19M$ 10M
2009-$ 30M$ 15M
2008$ 4M-$ 39M$ 24M
2007-$ 40M$ 53M
2006-$ 46M$ 26M
2005$ 134K-$ 58M$ 50M
2004$ 1M-$ 46M$ 32M
2003$ 1M-$ 24M$ 29M
2002$ 1M-$ 17M$ 19M
2001$ 1M-$ 11M$ 16M
2000$ 741K-$ 10M$ 18M
1999$ 178K-$ 4M$ 3M
1998$ 100K-$ 15M$ 1M
1997$ 700K-$ 9M$ 6M
1996$ 200K-$ 2M$ 200K
IPO1995$ 100K-$ 2M
WINT - Windtree Therapeutics Inc logo

Windtree Therapeutics Inc fundamental performance

Between 2014 and 2024, revenue declined from $ 2M to $ 0.00 and net income went from -$ 44M to -$ 5M. Revenue increased in 3 of those 10 years; net income in 5.

Between 2004 and 2024, revenue declined from $ 1M to $ 0.00 and net income went from -$ 46M to -$ 5M. Revenue increased in 7 of those 20 years; net income in 11.

Windtree Therapeutics Inc currently holds a 20-year HDB Score of 2.6 out of 10. How the HDB Score is calculated.

Membership

Continue WINT’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies